300119 瑞普生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.3388.7326.65610.3248.401
总资产报酬率 ROA (%)2.6395.1284.0176.9195.878
投入资产回报率 ROIC (%)3.1086.3245.0308.2566.800

边际利润分析
销售毛利率 (%)39.72941.27741.37643.64248.441
营业利润率 (%)13.95314.11212.15621.03119.990
息税前利润/营业总收入 (%)15.02114.87012.88321.84320.686
净利润/营业总收入 (%)12.89912.78410.74419.01017.933

收益指标分析
经营活动净收益/利润总额(%)96.51380.386103.12466.82585.140
价值变动净收益/利润总额(%)6.95223.381-0.42513.37713.396
营业外收支净额/利润总额(%)0.385-1.890-1.3250.253-0.683

偿债能力分析
流动比率 (X)1.6161.7861.6212.2242.362
速动比率 (X)1.3821.5201.3991.9072.081
资产负债率 (%)34.40032.27937.14428.85726.287
带息债务/全部投入资本 (%)26.27423.83524.91918.01717.485
股东权益/带息债务 (%)268.179305.683288.756441.069460.543
股东权益/负债合计 (%)175.150190.309151.073225.844262.994
利息保障倍数 (X)14.80914.58114.53728.79624.855

营运能力分析
应收账款周转天数 (天)112.415107.169118.848114.927113.600
存货周转天数 (天)86.54890.34899.652101.843121.862